source
- FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptomsClick Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the…
- Bankrupt Sangamo sells Fabry gene therapy to PTC and prion program to Lilly for $161MSangamo Therapeutics, currently in Chapter 11 bankruptcy, has agreed to divest its Fabry disease gene therapy and several other platforms to raise cash for the restructuring. PTC Therapeutics emer…